Pharmacological validation of TDO as a target for Parkinson’s disease
Paula Perez‐Pardo(Utrecht University), Aletta D. Kraneveld(Utrecht University), Antoon M. van Doornmalen(Center for Translational Molecular Medicine), Jan Gerard Sterrenburg(Center for Translational Molecular Medicine), Nicole Willemsen‐Seegers(Center for Translational Molecular Medicine), Michaela Tutone(Zambon (Italy)), Rogier C. Buijsman(Center for Translational Molecular Medicine), Youri Adolfs(Utrecht University), Joost C.M. Uitdehaag(Center for Translational Molecular Medicine), Jos de Man(Center for Translational Molecular Medicine), Joeri de Wit(Center for Translational Molecular Medicine), Yvonne Grobben(Center for Translational Molecular Medicine), Guido J.R. Zaman(GlaxoSmithKline (Netherlands)), Diep Vu‐Pham(Center for Translational Molecular Medicine), Michelle Müller(Center for Translational Molecular Medicine), Freek van Cauter(Center for Translational Molecular Medicine), Mitch Hartog(Utrecht University)
Cited by 29
Related Papers
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
|Proceedings of the National Academy of Sciences|1995|502
A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation
|Nature Medicine|2006|495
Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice
|Gut|2018|489
Altered gut microbiota and activity in a murine model of autism spectrum disorders
|Brain Behavior and Immunity|2013|436
Exploring Braak’s Hypothesis of Parkinson’s Disease
|Frontiers in Neurology|2017|388